PUBLICATIONS

PEER REVIEWED JOURNALS & BOOK CHAPTERS

2005

1.      Baran Y*, Gündüz U, Ural AU. Expression of multidrug resistance (MDR1) gene in human promyelocytic leukemia cell line selected with vincristine. Turkish Journal of Cancer, 2005; 35(2): 88-92.

2.      Önalan G*, Selam B, Baran Y, Cincik M, Onalan R, Gündüz U, Ural AU, Pabuççu R. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF. Human Reproduction, 2005; 20(9): 2391-2395.

2006

3.      Baran Y*, Gunduz U, Ural AU. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Experimental Oncology, 2006; 28(2): 163-165.

2007

4.      Gorduysus M*, Avcu N, Gorduysus O, Pekel A, Baran Y, Avcu F, Ural AU. Cytotoxic Effects of Four Different Endodontic Materials in Human Periodontal Ligament Fibroblasts. Journal of Endodontics, 2007; 33(12): 1450-1454.

5.      Ural AU*, Avcu F, Baran Y. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 2007; 110(2): 469-470.

6.      Baran Y*, Gunduz U.Kronik Miyelositer Lösemi Genetiği (Genetics of chronic myeloid leukemia).Journal of Turkish Internal Medicine, 2007; 3(2): 50-55

7.       Baran Y*, Gur B, Kaya P, Ural AU, Avcu F, Gunduz U. Upregulation of multidrug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology, 2007; 12(6): 511-517.

8.      Baran Y*, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology, 2007; 12(6): 497-503.

9.      Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B*. Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells. Journal of Biological Chemistry, 2007; 282(15): 10922-10934.

2008

10.  Baran Y*, Ural AU, Avcu F, Sarper M, Elçi P, Pekel A. Optimization of Transfection of Green Fluorescent Protein in Pursuing Mesenchymal Stem Cells, In Vivo. Turkish Journal of Hematology, 2008; 25(4): 172-175.

11.  Ural AU*, Avcu F, Baran Y. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Medical Oncology, 2008; 25(3): 350-355.

2009

12.  Abaan DO, Mutlu PK, Baran Y, Atalay MC, Gunduz U*. Multidrug Resistance Mediated by MRP1 Gene Overexpression in Breast Cancer Patients.Cancer Investigation, 2009; 27(2): 201-205.

13.  Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli Ua, Baran Y, Uslu R*. Docetaxel/Zoledronic Acid Combination Triggers Apoptosis Synergistically Through Downregulating Antiapoptotic Bcl-2 Protein Level In Hormone-Refractory Prostate Cancer Cells. Cell Biology International, 2009; 33(2): 239-246.

14.  Gucluler G, Baran Y*. Docetaxel Enhances the Cytotoxic Effects of Imatinib on Philadelphia Positive Human Chronic Myeloid Leukemia Cells. Hematology, 2009; 14(3): 139-144.

15.  Baran Y*, Oztekin C, Bassoy EY. Inhibition of Proteasome by Bortezomib Increased Chemosensitivity of BCR/ABL Positive Human K562 Chronic Myleoid Leukemia Cells to Imatinib. Health, 2009; 1(4): 320-324.

2010

16.  Ekiz A, Can G, Gunduz U, Baran Y*. Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts. Hematology, 2010; 15(1): 33-38.

17.  Goktas S, Baran Y, Ural AU, Yazici S*, Aydur E, Basal S,  Avcu F, Pekel A, Dirican B, Beyzadeoglu M. Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells. Urology,2010; 75(4): 793-798.

18.  Baran Y*, Oztekin C, Bassoy EY. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells. Cancer Investigation,2010; 28(6): 623-628.

19.  Ekiz HA, Baran Y*. Therapeutic Applications of Bioactive Sphingolipids in Hematological Malignancies. International Journal of Cancer, 2010; 127(7): 1497-506.

20.  Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N, Dalmizrak A, Kartal M, Gunduz U, Baran Y*. Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leukemia and Lymphoma, 2010; 51(10): 1895-901.

 

2011

21.  Cakir Z, Saydam G, Sahin F, Baran Y*. The Roles Of Bioactive Sphingolipids In Resveratrol-Induced Apoptosis In HL60 Acute Myeloid Leukemia Cells. Journal Of Cancer Research And Clinical Oncology, 2011; 137: 279–286.

22.  Avcı CB, Gunduz C, Baran Y, Sahin F, Yilmaz S, Dogan ZO, Saydam G*. Caffeic Acid Phenethyl Esther Triggers Apoptosis Through Induction of Loss of Mitochondrial Membrane Potential in CCRF-CEM. Journal of Cancer Research and Clinical Oncology, 2011; 137: 41-47.

23.  Can G, Ekiz A, Baran Y*. Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells. Hematology, 2011; 16(2): 95-99.

24.  Kartal M, Saydam G, Sahin, Baran Y*. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutrition and Cancer; An International Journal, 2011; 63(4): 637-644.

25.  Sanli MG, Turan T, Ekiz HA, Baran Y*. The importance of protein profiling in the diagnosis and treatment of hematologic malignancies. Turkish Journal of Hematology, 2011; 28: 1-14.

26.  Mutlu P, Baran Y, Ural AU, Avcu F, Dirican B, Beyzadeoglu M, Gündüz U*. Effect Of Cobalt-60 (Γ Radiation) On Multidrug Resistant Multiple Myeloma Cell Lines. Cell Biology International, 2011; 35(7): 721-5.

27.  Salas A, Ponnusamy S, Senkal CE, Meyers MA, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Ramasamy S, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart RK, Perrotti D, Ogretmen B*. : Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood, 2011; 117(22): 5941-5952.

28.  Ekiz HA, Baran Y*. Bioactive Sphingolipids in Response to Chemotherapy: A Scope on Leukemias. Anti-Cancer Agents in Medicinal Chemistry, 2011; 11: 385-397.

29.  Camgoz A, Gencer EB, Ural AU, Avcu F, Baran Y*. Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells. Leukemia and Lymphoma, 2011; 52(8): 1574-84.

30.  Firinci F*, Karaman M, Baran Y, Bagriyanik A, Ayyildiz ZA, Kiray M, Kozanoglu I, Yilmaz O, Uzuner N, Karaman O. Mesenchymal Stem Cells Ameliorate The Histopathological Changes in a Murine Model of Chronic Asthma. International Immunopharmacology, 2011; 11(8): 1120-1126.

31.  Avcı ÇB, Yılmaz S, Dogan ZO, Saydam G, Dodurga Y, Ekiz HA, Kartal M, Sahin F, Baran Y*, Gunduz C. Quercetin-induced Apoptosis involves increased HTERT enzyme activity of Leukemic Cells. Hematology, 2011; 16(5): 303-307.

32.  Baran Y*, Bielawski J, Gunduz U, Ogretmen B. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.  Journal of Cancer Research and Clinical Oncology,2011; 137(10): 1535-1544.

33.  Gencer EB, Ural AU, Avcu F, Baran Y*.A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes. Annals of Hematology, 2011; 90(11): 1265-1275.

34.  Avcu F, Avcu N*, Er N, Kansu Ö, Baran Y, Pekel A, Ural AU. The Cytotoxic and Apoptotic-Necrotic Effects of Whitening Materials on Human Gingival Fibroblasts.  Clinical Dentistry and Research, 2011; 35(1): 3-11.

35.  Baran Y, Zencir S, Çakır Z, Öztürk E, Topçu Z*.  Imatinib-induced apoptosis; A possible link to topoisomerase enzyme inhibition.Journal of Clinical Pharmacy and Therapeutics, 2011; 36(6): 673-679.

36.  Adan A, Kartal M, Baran Y*.Meme Kanserinin Moleküler Biyolojisi (Molecular Biology of Breast Cancer).2011,Kitap Bölümü,Meme Kanserine Moleküler Yaklaşım Molecular Approaches to Breast Cancer, ISBN: 978-975-483-928-9.

37.  Baran Y*. Hücrenin Kritik Kararı; Yaşamak ya da Ölmek. 2011, Kitap Bölümü, I. Hücre Ölümü Araştirma Teknikleri Teorik Kursu, ISBN: 978-975-441-349-6.

38.  Baran Y*. Hücre Ölümü Çalışmalarında Gen Aktarım Teknikleri. 2011, Kitap Bölümü, I. Hücre Ölümü Araştirma Teknikleri Teorik Kursu, ISBN: 978-975-441-349-6.

39.  Gucluler G, Piskin O, Baran Y*. The roles of antiapoptotic sphingosine kinase-1 and glucosylceramide genes in drug induced cell death of MCF-7 breast cancer cells. J BUON, 2011; 16(4): 646-651.

 

2012

40.  Ekiz HA, Can G, Baran Y*. Role of autophagy in the progression and suppression of leukemias. Critical Reviews in Hematology/Oncology, 2012; 81(3): 275-285.

41.  Bassoy EY and Baran Y*. Bioactive Sphingolipids in Docetaxel-Induced Apoptosis in Human Prostate Cancer Cells. Biomedicine And Pharmacotherapy, 2012; 66(2): 103-110.

42.  Purclutepe O, Iskender G, Kiper HD, Tezcanli B, Selvi N, Avci CB, Kosova B, Sahin F, Baran Y*, Saydam G. Enalapril-Induced Apoptosis of Acute Promyeloctic Leukemia Cells  Involves STAT5A. Anticancer Research, 2012; 32: 2885-2894.

43.  Ceylan C, Camgoz A, Baran Y*. Macromolecular changes in nilotinib resistant K562 cells; an in vitro study by Fourier transform infrared spectroscopy. Technology in Cancer Research & Treatment, 2012; 11(4): 333-344.

44.  Can G, Cakir Z, Kartal M, Gunduz U, Baran Y*. Apoptotic Effects of Resveratrol, a Grape Polyphenol, on Imatinib Sensitive and Resistant K562 Cronic Myeloid Leukemia Cells. Anticancer Research, 2012; 32(7): 2673-8.

45.  Baran Y*, Saydam G. Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. Journal of Blood Medicine, 2012; 3: 139–150.

46.  Bozcuk H, Abali H, Coskun S, Aydıner A, Çinkaya A, Demirkazık A, Özet A, Yolcu A, Balkan A, Çavdar A, Kefeli AÜ, Uluç BO, Atasoy B, Demirkan B, Yalçın B, Eroğlu C, Yalman D, Kılıç D, Tunalı D, Fırat D, Seber E, Üçgül Çavuşoğlu E, Ulukaya E, Kaytan Sağlam E, Tezcanlı E, Eryılmaz E, Dinçbaş FÖ, Telli F, Yumuk F, Başaran G, Çağlar HB, Sönmez H, Yılmaz H, Engin H, Helvacı K, Sönmez K, Koral L, Artaç M, Fuat Eren M, Koçar M, Beyzadeoğlu M, Akın M, Benekli M, Cengiz M, Erman M, Yıldız M, Doğan M, Balkan M, Eraktuğ N, Ünal OÜ, Şencan O, Erpolat Ö, Saip P, Kılıçkap S, Selçuk Seber SO, Paydaş S, Sarıhan S, Kömürcü Ş, Demirkasımoğlu T, Korkmaz T, Yetişyiğit T, Yavuzşen T, Evrensel T, Akman T, Abacıoğlu U, Kefeli U, Egeli Ü, Elgin Y, Baran Y, Bulut Z (Alphabetical order). The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. World Journal of Surgical Oncology,2012; 10(1): 161-167.

47.              Kozanoğlu İ*, Baran Y. Hematoloji laboratuarında moleküler tanı yöntemlerinin kullanılması (The use of molecular diagnostic methods in hematology laboratory). Turkiye Klinikleri J Hem Onc-Special Topics, 2012; 5(4): 87-93.

 

2013

48.              Gokbulut AA, Yandım MK, Iskender G, Baran Y*. Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer. Current Medicinal Chemistry, 2013; 20: 108-122.

49.              Yandım MK, Apohan E, Baran Y*. Therapeutic Potential of Targeting Ceramide/Glucosylceramide Pathway in Cancer. Cancer Chemotherapy and Pharmacology, 2013; 71(1): 13-20.

50.              Kozanoglu I, Yandim MK, Cincin ZB, OzdoguH, Cakmakoglu B, Baran Y*.New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. Journal of Cancer Research and Clinical Oncology. 2013; 139(2): 327-335.

51.              Kaymaz BT, Selvi N, Adan Gokbulut A, Aktan Ç, Gündüz C, Saydam G, Şahin F, Çetintaş VB, Baran Y, Kosova B*. Suppression of STAT5A and STAT5B Chronic Myeloid Leukemia Cells via siRNA and Antisense-Oligonucleotide Applications with the Induction of Apoptosis. American Journal of Blood Research, 2013; 3(1): 58-70.

52.              Baran Y*, Ceylan C, Camgoz A. The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy. Biomedicine and Pharmacotherapy, 2013; 67: 221-227.

53.              Senarisoy M, Canturk P, Zencir S, Baran Y, Topcu Z*. Gossypol interferes with both type I and type II topoisomerases activities without generating strand breaks. Cell Biochemistry and Biophysics, 2013; 66(1): 199-204.

54.              Turan T, Sanlı-Mohamed G*, Baran Y*. Changes in Protein Profiles of Multiple Myeloma Cells in Response to Bortezomib.Leukemia and Lymphoma, 2013; 54(5): 1061-1068.

55.              Camgoz A, Gencer EB, Ural AU, Baran Y*. Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance. Leukemia and Lymphoma, 2013; 54(6): 1279-1287.

56.              Sunay O, Can G, Cakir Z, Denek Z, Kozanoğlu I, Erdil G, Mustafa M, Baran Y*. Autologous Rabbit Adipose Tissue Derived Mesenchymal Stem Cells For The Treatment Of Bone Injuries With Distraction Osteogenesis. Cytotherapy, 2013; 15(6): 690-702.

57.              Firatligil B, Avci CB, Baran Y*. mir-17 in Imatinib Resistance and Response to Tryosine Kinase Inhibitors in Chronic Myeloid Leukemia Cells. J. BUON, 2013; 18(2):437-441.

58.              Gokbulut AA, Apohan E, Baran Y*. Resveratrol and quercetin induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology, 2013; 18(3):144-50.

59.              Bozkurt S, Özkan T, Özmen F, Baran Y, Sunguroğlu A, Kansu E. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells. Hematology, 2013, 18(4): 217-223.

60.              Kiper HD, Tezcanli B, Gokbulut AA, Selvi N, Avci CB, Kosova BK, , Iskender G, Yandım MK, Gunduz C, Sahin F, Baran Y*, SaydamG. STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Biomedicine and Pharmacotherapy, 2013; 67(6):527-532.

61.              Can G, Akpinar B, Baran Y, Zhivotovsky B, Olsson M*. 5-Fluouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene, 2013; 32(38):4529-4538.

62.              Comert M, Baran Y*, Saydam G. Changes in moleculer biology of Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor era. 2013; (3):191-200.American Journal of Blood Research.

63.              Yilmaz AF, Saydam G, Sahin F, Baran Y*. Granulocytic Sarcoma: A Systematic Review. American Journal of Blood Research, 2013;3(4):265-270.

 

2014

64.              Ömür Ö*, Baran Y, Oral A, Ceylan Y. Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography For Extranodal Staging Of Non-Hodgkin Lymphoma And Hodgkin Disease.Diagnostic and Interventional Radiology2014;0(2):185-192.

65.              Avci CB, Baran Y*. Micro RNAs in Personilized medicine. Methods in Molecular Biology; miRNomics: MicroRNA Biology and Computational Analysis, Humana Press, 2014, 1107:311-25

66.             Aydemir LY, Adan Gokbulut A, Baran Y, Yemenicioglu A*. Bioactive, functional and edible film making properties of different protein isolates from Turkish hazelnut (Corylus avellana L.) meal obtained from oil extraction. Food Hydrocolloids, 2014; 36:130-142.

67.              Solmaz S, Gokbulut AA, Cincin B, Ozdogu H, BogaC, Cakmakoglu B, Kozanoglu I, Baran Y*. Therapeutic Potential of Apigenin, a Plant Flavonoid, for Imatinib-Sensitive and Resistant Chronic Myeloid Leukemia Cells. Nutrition and Cancer; An International Journal, 2014; 66(4):599-612.

68.              Celikkanat D, Baran Y*. Comparative development of knowledge-based bioeconomy in the European Union and Turkey.  Critical Reviews in Biotechnology, 2014; 34(3): 269-280.

69.              Omur O, Baran Y.  An Update on Molecular Biology of Thyroid Cancers. Critical Reviews in Oncology/Hematology, 2014; 90(3):233-252.

70.              Cincin ZB, Unlu M, Kıran B, Bireller ES, Baran Y*, Cakmakoglu B*. Molecular Mechanisms of Quercitrin-Induced Apoptosis in Non Small Cell Lung Cancer Cells. Archives of Medical Research,2014; 45(6):445-454.

71.              Gokbulut AA, Baran Y*.A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells. In Press, 2014,Turkish Journal of Hematology.

72.              Kiraz Y, Unlu M, Kartal Yandim M, Baran Y*. Molecular Biology of Stem Cells. In Press, 2014, Hematolog (Invited Book Chapter).

73.              Ünlü M, Kiraz Y, Kacı FN, Baran Y*. Multidrug Resistance In Chronic Myeloid Leukemia. In Press, 2014, Turkish Journal of Biology.

74.              Cincin ZB, Unlu M, Kıran B, Bireller ES, Baran Y*, Cakmakoglu B*. Apoptotic Effects of Quercitrin in DLD-1 Colon Cancer Cell Lines. In Press, 2014, Pathology and Oncology Research.

75.              Katgı A, Sevindik OG, Gokbulut AA, Ozsan HG, Yuksel F, Solmaz SM, Alacacıoglu I, Ozcan MA, Demirkan F, Baran Y, Piskin O.  Nilotinib Does Not Alter the Secretory Funcions of Carotid Artery Endothelıal Cells in a Prothrombotic or Antithrombotic Fashion. In Press, 2014, Clinical and Applied Thrombosis/Hemostasis.

76.              Kartal Yandım M, Adan Gokbulut A, Baran Y*. Molecular Mechanisms of Drug Resistance and its Reversal in Cancer. Under Revision, 2014, Critical Reviews in Oncology/Hematology.

77.              Tufekçi O, Yandim MK, Oren H, Irken G, Baran Y*. Targeting FOXM1 Transcription Factor In T-Cell Acute Lymphoblastic Leukemia. Under Revision, 2014, Leukemia Research.

78.             

*Corresponding Author

 

ABSTRACTS PUBLISHED IN INTERNATIONAL CONFERENCES

2004

1-                 Baran Y, Gündüz U, Ural AU. Investigations of cross-resistance to cytarabine in human promyelocytic leukemia cell line selected for resistance to Vincristine. 6th Balkan Meeting on Human Genetics, August 28-31 2004, Thessaloniki, Greece, p.66.

2005

2-                 Kars DM, İşeri DÖ, Atalay C, Baran Y, Kaya P, Gündüz U. Investigation of molecular mechanisms of multiple drug resistance in different cell lines and tissue types. The European COST action B16 Symposium on Multidrug Resistance Reversal, May 13-14 2005, Antalya, Turkey, p.35.

3-                 Avcu F, Ural AU, Baran Y, Sobacı G, Deveci M, Çetin A, Pekel A, Sarper M, Elçi P, Gündüz U. A photodynamic pathway to apoptosis induced by hypericin in human myeloma ARH-77 cell line: Possible relevance to photodynamic therapy. The 47th American Society of Hematology Annual Meeting and Exposition, 2005, p.351B.

2006

4-                 Baran Y, Şenkal CE, Bielawski J, Öğretmen B, Gündüz U. Overcoming the chemoresistance in human chronic myeloid leukemia K562 cells by siRNA inhibition of sphingosine kinase-1. Haematologica, 11th Congress of European Hematology Association, June 15-18 2006, Amsterdam, Netherlands, p.15.

5-                 Baran Y, Şenkal CE, Bielawski J, Öğretmen B, Gündüz U. Ceramide glycosylation by glucosyl ceramide synthase inhibits the apoptotic effect imatinib on human K562 and Meg-01 cells. Haematologica, 11th Congress of European Hematology Association, June 15-18 2006, Amsterdam, Netherlands, p.125.

6-                 Baran Y, Şenkal CE, Bielawski J, Öğretmen B, Gündüz U. The involvement of C:18 ceramide and human longevity assurance genes in imatinib induced apoptosis. Haematologica, 11th Congress of European Hematology Association, June 15-18 2006, Amsterdam, Netherlands, p.124.

7-                 Baran Y, Ural AU, Öğretmen B, Gündüz U. Multidrug resistance mechanisms in human chronic myeloid leukemia cells. Haematologica, 11th Congress of European Hematology Association, June 15-18 2006, Amsterdam, Netherlands, p.16.

8-                 Baran Y, Gündüz U, Şenkal BE, Bielawski J, Öğretmen B. The involvement of ceramides in imatinib induced apoptosis and drug resistance. Balkan journal of Medical Genetics, 7th Balkan Meeting on Human Genetics, August 31-September 2 2006, Scopje, Macedonia, p.44.

9-                 Baran Y, Gündüz U, Ural AU, Öğretmen B. Apoptotic pathways induced by imatinib in sensitive and imatinib-resistant K562 cells. Balkan Journal of Medical Genetics, 7th Balkan Meeting on Human Genetics, August 31-September 2 2006, Scopje, Macedonia, p.127.

10-             Baran Y, Gündüz U, Bielawski J, Öğretmen B. Circumventing multi-drug resistance by a combination therapy of imatinib and GCS inhibitor in resistant human chronic myeloid leukemia cells. Balkan J of Medical Genetics, 7th Balkan Meeting on Human Genetics, August 31-September 2 2006, Scopje, Macedonia, p.127.

11-             Baran Y, Gündüz U, Öğretmen B. The sequence analyses of imatinib mesylate binding site of Abl kinase domain in sensitive and imatinib-resistant human CML cells. Balkan J of Medical Genetics, 7th Balkan Meeting on Human Genetics, August 31-September 2 2006, Scopje, Macedonia p.128.

12-             Baran Y, Salas A, Şenkal CE, Bielawski J, Gündüz U, Obeid LM, Öğretmen B. Alterations of human longevity assurance gene1 (LASS1)/Sphingosine Kinase-1-dependent ceramide generation and metabolism involve in the regulation of imatinib-induced apoptosis and resistance in K562 human chronic myeloid leukemia. The 41st South Eastern Regional Lipid Conference, November 1-3 2006, Cashiers, NC, USA, p.50.

2007

13-             Uyuklu T, Ural AU, Sarper M, Avcu F, Baran Y, Elci P,  Akar N.A Study of Multiple Drug Resistance Mechanisms Improved Against Bortezomib on Multiple Myeloma Cell Lines In Vitro. The 49th American Society of Hematology Annual Meeting and Exposition, December 8-11 2007, Georgia, Atlanta, USA, p.113B.

2008

14-             Avcu F, Ural AU, Sarper M, Uyuklu T, Baran Y, Safali M, Elçi P. The effects of proteasome inhibitor bortezomib on osteoblast differentiation of human bone marrow derived multipotent mesenchymal stem cells, In Vitro. 14th Annual International Society for Cellular Therapy Meeting, May 17-20 2008,  Miami, Florida, USA, p.55.

15-             Gucluler G, Baran Y. Docetaxel Enhances The Cytotoxic Effects Of Imatinib In Philadelphia Positive Human Chronic Myeloid Leukemia Cells. 32nd World Congress of International Society of Hematology, 19-23 October 2008, Bangkok, Thailand, p.32.

16-             Durcan C, Ugur AU, Ferit A, Baran Y.Inhibition Of Ceramide Turnover By Glucosyle Ceramide Inhibitor, PDMP, Increased Dasatinib-Induced Apoptosis. 32nd World Congress of International Society of Hematology, 19-23 October 2008, Bangkok, Thailand, p 108.

17-             Bassoy EY, Ozcimen B, Durcan C, Can G, Yusuf B.Inhibition Of Proteasome By Bortezomib Increased Chemosensitivity Of BCR/ABL Positive K562 Human Chronic Myleoid Leukemia Cells To Imatinib. 32nd World Congress of International Society of Hematology, 19-23 October 2008, Bangkok, Thailand, p108.

18-             Durcan C, Ural AU, Avcu F, Baran Y. Targeting Conversion Of Apoptotic Ceramide To Antiapoptotic Glucosyle Ceramide Increased Cytotoxic Effects Of Nilotinib In Ph(+) Human Chronic Myeloid Leukemia Cells. 32nd World Congress of International Society of Hematology, 19-23 October 2008, Bangkok, Thailand, p.109.

19-             Durcan C, Seher G, Bassoy EY, Can G, Baran Y.Combination Of Fludarabine And Imatinib-Induced Apoptosis Through Loss Of Mitochondrial Membrane Potential And Caspase-3 Enzyme Activity In Human K562 Chronic Myleloid Leukemia Cells. 32nd World Congress of International Society of Hematology, 19-23 October 2008, Bangkok, Thailand, p.33.

2009

20-             Baran Y, Güçlüler G. The Involvement Of Glucosyle Ceramide Synthase Gene On Induction Of Apoptosis In Response To Different Anticancer Agents In Mcf-7 Breast Cancer Cells. 8th Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.104.

21-             Bassoy EY, Gencer EB, Baran Y.The role of LASS1 gene and ceramide accumulation in docetaxel-induced apoptosis in hormone resistant DU-145 and PC-3 Prostate Cancer Cells. 8th Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.111.

22-             Bassoy EY, Kartal M, Baran Y.The Involvement of Glucosyle Ceramide Synthase in Docetaxel-Induced Apoptosis in Human DU-145 and PC-3 Prostate Cancer Cells. 8th Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.108-109.

23-             Baran Y, Güçlüler G. The Role Of Sphingosine Kinase-1 Which Converts Apoptotic Sphingosine To Antiapoptotic Sphingosine-1-Phosphate In Docetaxel, Paclitaxel, Doxorubicin, Cyclophosphamide And Tamoxifen Induced Apoptosis In Mcf-7 Breast Cancer Cells. 8th Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.110.

24-             Baran Y, Bassoy EY, Cakir Z. Inhibition of Conversion of Apoptotic Sphingosine Molecule to Antiapoptotic Sphingosine-1-Phosphate Increased Sensitivity of Prostate Cancer Cells to Docetaxel. 8th Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.110.

25-             Deveci D, Yüce H, Baran Y. A case Report with Trisomy 8 Mosaicism. 8Pth Balkan Meeting On Human Genetics, 14-17 May 2009, Dubrovnik, Croatia, p.30.

26-             Baran Y, Gencer EB, Ural AU, Avcu F. Accumulation of Apoptotic Ceramides Increased Apoptotic Effects of Nilotinib in Philadelphia Positive Meg-01 Cells Synergistically. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.570.

27-             Gencer EB,Ural AU, Avcu F, Baran Y. Targeting Ceramide Metabolism Increased Sensitivity of Philadelphia Positive Chronic Megacaryoblastic Leukemia Cells to Dasatinib. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.132.

28-             Baran Y, Gencer EB, Ural AU, Avcu F. Increasing De Novo Synthesis of Ceramides Increased Nilotinib Induced Apoptosis in Human Meg-01 Chronic Megacaryoblastic Cells. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.569.

29-             Çakır Z, Saydam G, Şahin F, Baran Y. The Effects of Ceramide, Glucosylceramide and Sphingosine 1 Phosphate in Resveratrol Induced Cell Death in HL60 Acute Promyelocytic Leukemia Cells. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.540-541.

30-             Kartal M, Saydam G, Şahin F, Baran Y. Increasing Intracellular Generation or Accumulation of Ceramides Increased Cytotoxic Effects of Resveratrol in Human K562 Chronic Myeloid Leukemia Cells. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.497.

31-             Baran Y, Can G, Ekiz A, Genç Ş. Imatinib Induces Autophagy Through Increasing the Expression Levels of Beclin-1 And Atg-5 Genes in Both Parental Sensitive and Imatinib-Resistant K562 Cells. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.233.

32-             Baran Y, Can G, Ekiz A. Nilotinib Significantly Induces Apoptosis in Imatinib Resistant K562 Cells, As Effectively As in Parental Sensitive Counterparts. 14th Congress of European Hematology Association, 04-07 June 2009, Berlin, Germany, p.343.

33-             Gencer EB, Ural AU, Avcu F, Baran Y. Dasatinib induces apoptosis through increasing de novo generation or accumulation of ceramides in human K562 and Meg-01 chronic myeloid leukemia cells. Lipid Signalling and Diseases Congress, 9-15 September 2009, Ortona, Italy, p.46.

34-             Baran Y, Güçlüler G. Anticancer Agents Used for the Treatment of Breast Cancer Induces Apoptosis Through Downregulating Antiapoptotic Sphingosine Kinase-1 and Glucosylceramide Synthase Genes in MCF-7 Cells. Lipid Signalling and Diseases Congress, 9-15 September 2009, Ortona, Italy, p.38-39.

35-             Çakır Z, Saydam G, Şahin F, Baran Y.Resveratrol Induces Apoptosis Through Induction of Accumulation of Ceramides in Human HL-60 Acute Premyelocytic Cells. Lipid Signalling and Diseases Congress, 9-15 September 2009, Ortona, Italy, p.40.

36-             Goktas S, Ural AU, Baran Y, Yazici S, Aydur E, Avcu F, Pekel A, Dirican B. Beyzadeoglu, M. Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity In Androgen Independent Human Prostate Cancer Cells. 104th Annual Meeting of the American-Urological-Association, 25-30 April 2009, Chicago, IL, USA.

2010

37-             Can G, Baran Y. Apoptotic Effects Of Resveratrol On Imatinib Sensitve and Resistant Chronic Myeloid Leukemia Cells. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.

38-             Baran Y, Camgoz A, Can G. Expression Analysis Of 84 Genes Involved In Different Signalling Pathways Of Cancer In Chronic Myeloid Leukemia Cells In Response To Nilotinib. Inhibition. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.

39-             Baran Y, Zincir S, Çakır Z, Ozturk E, Topçu Z. Imatinib-İnduced Apoptosis; A Possible Link To Topoisomerase Enzyme Inhibition. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.

40-             Baran Y, Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N. Suppression of STAT5a Increases Chemotherapeutic Sensitivity in Imatinib-Resistant and Imatinib-Sensitive K562 Cells. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.

41-             Baran Y, Kartal M, Can G. Molecular Mechanisms of Resveratrol-Induced Cell Death in K562 Chronic Myeloid Leukemia Cells. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.

42-             Baran Y, Cakir Z, Can G, Saydam G, Sahin F. Gene Expression Profiles In Resveratrol Applied Acute Promyelocytic Leukemia Cells. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.

43-             Baran Y, Camgoz A, Gencer EB, Ural AU, Avcu F. A Novel Mechanism Of Nilotinib-Induced Apoptosis; Bioactive Sphingolipids. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.

44-             Baran Y, Kartal M, Cakir Z, Saydam G, Sahin F. Ceramides Regulate Resveratrol-Induced Apoptosis In Human Acute Promyelocytic And Chronic Myeloid Leukemia Cells. 15th Congress of European Hematology Association, 10-13 June 2010, Barcelona, Spain.

45-             Baran Y, Bassoy EY, Cakir Z, Camgoz A, Gencer EB, Kartal M, Can G, Ekiz HA, Gucluler G.Therapeutic Potential of Targeting Sphingolipid Signaling Pathways in Various Types of Cancers. 21st Meeting of European Association for Cancer Research, 26-29 June 2010, Oslo, Norway.

46-             Baran Y, Camgoz A, Can G. Changes in Expression Profiles of Apoptosis, Invasion, Metastasis, Angiogenesis, Transcription Factors, Cell Cycle Control and Tumor Supressor Genes in Nilotinib Treated Chronic Myeloid Leukemia Cells. 21st Meeting of European Association for Cancer Research, 26-29 June 2010, Oslo, Norway.

47-  Can G, Baran Y. Cytotoxic effects of resveratrol on imatinib sensitive and resistant K562 chronicmyeloid leukemia cells. 21st Meeting of the European-Association-for-Cancer-Research 26-29 June 2010, Oslo, Norway.

48-             Cakır Z, Baran Y, Can G, Saydam G, Sahin F. Gene Expression Profiles in Resveratrol-Induced Cell Death in Acute Promyelocytic Leukemia Cells. 21st Meeting of European Association for Cancer Research, 26-29 June 2010, Oslo, Norway.

49-             Baran Y, Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N. The roles of STAT transcription Factors in imatinib resistance and sensitivity in BCR/ABL positive chronic myeloid leukemia cells. 21st Meeting of European Association for Cancer Research, 26-29 June 2010, Oslo, Norway.

2011

50-             Baran Y, Camgoz A, Ural AU, Avcu F. Molecular Mechanisms Of Nilotinib Resistance And Reversal Of Resistance In Chronic Myeloid Leukemia Cells. 16th Congress of European Hematology Association, 9-12 June2011, London, UK.

51-             Baran Y, Cakir Z. Combination Of Resveratrol And Nilotinib Inhibits Cell Proliferation And Induce Apoptosis Synergistically In Chronic Myeloid Leukemia Cells. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.

52-             Baran Y, Cakir Z. Determination Of Cytotoxic Effects Of Gossypol On Multiple Myeloma Cells. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.

53-             Baran Y, Sunay O, Çakır Z, Can G, Denek Z, Kozanoğlu I, Yılmaz M. Therapeutic Potentials Of Mesenchymal Stem Cells In Bone Defects, The Case Study In Rabbit Tibia. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.

54-             Baran Y, Camgoz A, Ceylan C. Analyses Of Macromolecules In Nilotinib Resistance By Fourier Transform Infrared Spectroscopy. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.

55-             Baran Y, Camgoz A, Ceylan C. The roles of Macromolecules in Imatinib Resistance in Chronic Myeloid Leukemia. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.

56-             Baran Y, Gencer EB, Güçlüler G. Apoptotic Effects of Sunitinib on Multıple Myeloma Cells. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.

57-             Baran Y,Kozanoglu I, Kartal M, Ozdogu H, Sarıalioglu F. A new indication for an old drug; Therapeutic potential of propranolol on human multiple myeloma cells. 16th Congress of European Hematology Association, 9-12 June 2011, London, UK.

58-  Firinci F, Karaman M, Baran Y, Bagriyanik A, Ayyildiz ZA, Kiray M, Kozanoglu I, Yilmaz O, Uzuner N, Karaman O. Mesenchymal Stem Cells Ameliorate The Histopathological Changes In A Murine Model Of Chronic Asthma.30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), 11-15 June2011, Istanbul, Turkey.

59-             Gökbulut AA, Kartal M, Yaşar M, Baran Y. A Promising New Anticancer Agent, KL-21, Inhibits Proliferation And Cell Cycle Progression And Induces Apoptosis In Chronic Lymphocytic Leukemia Cells But Has No Effect On Healthy Cells. EACR Anticancer Agents Research Congress. 13-16 October2011, Antalya, Türkiye.

60-             Baran Y, Kartal M, Kozanoğlu İ. A Natural Product, Quercetin Enhances The Cytotoxic And Apoptotic Effects Of Dexamethasone On Jurkat Cells.Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.

61-             Baran Y, Gökbulut AA, Yasar M. A Novel Agent, KL-21, Has Significant Anticancer Potential On Chronic Lymphocytic Leukemia Cells But Not In Healthy Cells. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.

62-             Baran Y, Gökbulut AA, Apohan E, Pişkin O, Ozcan MA. Quercetın Induced Apoptosis In 232b4 Chronic Lymphocytic Leukemia Cells. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.

63-             Baran Y, Gökbulut AA, Ozcan MA, Pişkin O, Unlü M. Antiproliferative And Apoptotic Effects Of Resveratrol On Chronic Lymphocytic Leukemia Cells. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.

64-             Baran Y, Turan T, Sanlı-Mohamed G. Changes In Protein Profiles Of Multiple Myeloma Cells In Response To Bortezomib. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.

65-             Saydam G, Kiper HD, Tezcanli B, Selvi N, Avci CB, Baran Y, Kosova B, Sahin F. Zoledronate Induces Apoptosis via Effecting on STAT Pathway in Chronic Myeloid Leukemia Cells. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.

66-             Sahin F, Purclutepe O, Kiper HD, Tezcanli B, Selvi N, Avci CB, Baran Y, Kosova B, Saydam G, Enalapril Maleate has Cytotoxic Effect in HL60 Leukemic Cells By Altering STAT Signaling Pathway. Haematologica, 17th Congress of European Hematology Association, 14-17 June 2012, Amsterdam, Netherlands.

67-             Kayabasi C,Avci CB, Susluer SY, Balci T,Baran Y,Saydam G,Gunduz C. Autophagic and Apoptotic Effects of Tyrosine Kinase Inhibitors in Myeloid Leukemia: Comparison of Three Generation. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), 8-11 December 2012 Atlanta, USA.

2013

68-             Baran Y, İskender G, Piskin O, Ozcan MA. Determination of the Cytotoxic and Apoptotic Effects of Caffeic Acid Phenethyl Ester and Gossypol in Combination with Fludarabine at a Molecular Level in Acute Lymphoblastic Leukemia Cells. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.

69-             Baran Y, Gokbulut AA, Cincin ZB, Cakmakoglu B, Kozanoglu I. Changes in Gene Expression Profiles in Response to Apigenin in Imatinib Sensitive and Resistant Chronic Myeloid Leukemia Cells. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.

70-             Baran Y, Gokbulut AA, Solmaz A, Kozanoglu I, Ozdogu H. Effects of Apigenin on Imatinin-Sensitive And Resistant Chronic Myeloid Leukemia Cells. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.

71-             Baran Y, Yilmaz S, Cincin ZB, Cakmakoglu B, Kozanoglu I, Ozdogu H. Cytotoxic Effects of Apigenin on Multiple Myeloma Cells. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.

72-             Baran Y, Yandim MK, Kozanoglu I, Ozdoğu H, Piskin O, Ozcan MA, Saydam G, Sahin F, Avcu F, Ural AU. Diagnostic and Therapeutic Potentials of Expression Levels of Bioactive Sphingolipid Genes in Newly Diagnosed and Drug-Resistant Chronic Myeloid Leukemia Patients. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.

73-             Katgı A, Gökbulut AA, Sevindik ÖG, Yüksel F, Solmaz SM, Özsan GH, Baran Y, Pişkin O. Effect of Nilotinib on the Function of Carotid Artery Endothelial Cells. 18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.

74-             Kozanoglu I, Aygun B, Boga I, Cansun C, Oktar N, Maytalman E, Baran Y, Boga C, Ozdogu H. Immunologically Detection of Bcr/Abl Fusion Protein with Flow Cytometry in K562 Chronic Myeloid Leukemia Cellsand Comparison with RT-PCR Results.  18th. Congress of European Hematology Association, 13-17 June 2013, Stockholm, Swiss.

75-             Avcı CB, Kayabasi C, Susluer SY, Balci T, Saydam G, Baran Y, Gunduz C. Ponatinib regulates major signaling pathways in imatinib-resistant chronic myeloid leukemia cells. European Cancer Congress on Reinforcing Multidisciplinarity, 27 September-1 October 2013,Amsterdam, Netherlands.

76-             Tufekci O, Yandim MK, Oren H, Irken G, Baran Y. Targeting FOXM1 Transcription

Factor In T-Cell Acute Lymphoblastic Leukemia.55th Annual Meeting of the American-Society-of-Hematology, 7-10 December 2013, New Orleans, LA, USA.

 

2014

 

77-             Kozanoglu I, Unver G, Sariturk C, Baran Y, Yeral M, Boga C, Ozdogu H. Comparison of Ishage-Based Cd34 (+) Cell Enumeratİon Protocols On Bd Facs Canto II And Attune Flow Cytometers. 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, 30 March - 2 April 2014, Milan, Italy.

78-        Isik S, Karaman M, Baran Y, Kiray M, Caglayan-Sozmen S, Bagriyanik HA, Kozanoglu I, Gokbulut AA, Karaman O, Uzuner N. The effect of mezenchimal stem cells on lung and nasal histopathology and cytokin levels in a murine model of allergic rhinitis. European Academy of Allergy and Clinical Immunology Congress, 7-11 Haziran 2014, Copenhagen, Denmark.

79-   

 

ABSTRACTS PUBLISHED IN NATIONAL CONFERENCES

We have more than 100 abstracts published in national meetings.